PSA test gets a better grade from USPSTF—it’s a “C” Uncertainty lingers about high-risk groups

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Relying largely on maturing data from the European trials of screening for prostate cancer, the U.S. Preventive Services Task Force has given a better grade—a “C”—to screening for prostate cancer.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Editor & Publisher


President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H.  “The discretionary request calls for $6.5 billion to...

Editor & Publisher